CN104903327B - 用于治疗疼痛的作为autotaxin抑制剂的吡啶并-或吡咯并-稠合嘧啶衍生物 - Google Patents

用于治疗疼痛的作为autotaxin抑制剂的吡啶并-或吡咯并-稠合嘧啶衍生物 Download PDF

Info

Publication number
CN104903327B
CN104903327B CN201480004482.6A CN201480004482A CN104903327B CN 104903327 B CN104903327 B CN 104903327B CN 201480004482 A CN201480004482 A CN 201480004482A CN 104903327 B CN104903327 B CN 104903327B
Authority
CN
China
Prior art keywords
dihydro
base
milliliters
pyrimidine
gram
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480004482.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104903327A (zh
Inventor
T.J.博尚
稻茵
S.B.琼斯
B.H.诺尔曼
L.A.普菲菲尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN104903327A publication Critical patent/CN104903327A/zh
Application granted granted Critical
Publication of CN104903327B publication Critical patent/CN104903327B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
CN201480004482.6A 2013-01-11 2014-01-07 用于治疗疼痛的作为autotaxin抑制剂的吡啶并-或吡咯并-稠合嘧啶衍生物 Active CN104903327B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361751363P 2013-01-11 2013-01-11
US61/751363 2013-01-11
US201361777201P 2013-03-12 2013-03-12
US61/777201 2013-03-12
PCT/US2014/010400 WO2014110000A1 (en) 2013-01-11 2014-01-07 Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain

Publications (2)

Publication Number Publication Date
CN104903327A CN104903327A (zh) 2015-09-09
CN104903327B true CN104903327B (zh) 2016-09-07

Family

ID=50031555

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480004482.6A Active CN104903327B (zh) 2013-01-11 2014-01-07 用于治疗疼痛的作为autotaxin抑制剂的吡啶并-或吡咯并-稠合嘧啶衍生物

Country Status (13)

Country Link
US (1) US8969555B2 (US20070167479A1-20070719-C00034.png)
EP (1) EP2943494B1 (US20070167479A1-20070719-C00034.png)
JP (1) JP6285461B2 (US20070167479A1-20070719-C00034.png)
KR (1) KR101757997B1 (US20070167479A1-20070719-C00034.png)
CN (1) CN104903327B (US20070167479A1-20070719-C00034.png)
AU (1) AU2014205642B2 (US20070167479A1-20070719-C00034.png)
BR (1) BR112015015812A2 (US20070167479A1-20070719-C00034.png)
CA (1) CA2893253C (US20070167479A1-20070719-C00034.png)
EA (1) EA025106B1 (US20070167479A1-20070719-C00034.png)
ES (1) ES2636248T3 (US20070167479A1-20070719-C00034.png)
MX (1) MX2015008971A (US20070167479A1-20070719-C00034.png)
TW (1) TWI499591B (US20070167479A1-20070719-C00034.png)
WO (1) WO2014110000A1 (US20070167479A1-20070719-C00034.png)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201500356A (zh) * 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物
LT3071561T (lt) 2013-11-22 2021-08-25 Sabre Therapeutics Llc Autotaksino inhibitorių junginiai
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US10632104B2 (en) 2015-05-27 2020-04-28 Sabre Therapeutics Llc Autotaxin inhibitors and uses thereof
EP3302465A1 (en) 2015-06-05 2018-04-11 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
US10961242B2 (en) 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
JP7274767B2 (ja) * 2018-05-24 2023-05-17 ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 芳香族複素環式化合物及びその医薬組成物
AU2019308231B2 (en) * 2018-07-16 2022-12-22 The Scripps Research Institute Opioid haptens, conjugates, vaccines, and methods of generating antibodies
WO2020156459A1 (zh) 2019-02-01 2020-08-06 湖北生物医药产业技术研究院有限公司 吡咯并嘧啶衍生物及其用途
BR112022004099A2 (pt) * 2019-09-06 2022-05-31 Wuhan Humanwell Innovative Drug Res And Development Center Limited Company Composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma doença relacionada ao atx
AU2020349516A1 (en) * 2019-09-17 2022-03-17 Bial-R&D Investments, S.A. Substituted imidazole carboxamides and their use in the treatment of medical disorders
CN112778334B (zh) * 2019-11-07 2022-04-15 广州市恒诺康医药科技有限公司 芳杂环化合物、其药物组合物及其应用
WO2021115375A1 (zh) * 2019-12-11 2021-06-17 四川海思科制药有限公司 含氮杂环类自分泌运动因子抑制剂及其组合物和用途
WO2022022569A1 (zh) * 2020-07-28 2022-02-03 武汉人福创新药物研发中心有限公司 含氮杂环化合物的固体形式及其药物组合物和用途
WO2022022570A1 (zh) * 2020-07-28 2022-02-03 武汉人福创新药物研发中心有限公司 含氮杂环化合物的盐及其盐的固体形式、药物组合物和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032632A2 (en) * 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
WO2006119504A2 (en) * 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
US20070249631A1 (en) * 2004-04-28 2007-10-25 Gruenenthal Gmbh Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds
WO2012009258A2 (en) * 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003104230A1 (ja) 2002-06-07 2005-10-06 協和醗酵工業株式会社 二環性ピリミジン誘導体
JP5697601B2 (ja) * 2008-12-01 2015-04-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 癌に対するオータキシン阻害剤としての２，５−ジアミノ−置換ピリド［４，３−ｄ］ピリミジン
CN103201262B (zh) * 2010-08-20 2016-06-01 艾米拉医药股份有限公司 自分泌运动因子抑制剂及其用途
WO2013054185A1 (en) * 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
CN106220572B (zh) * 2011-10-28 2019-12-13 因西必泰克新有限公司 哒嗪衍生物的化合物、用途、组合物和试剂盒及制备方法
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
TW201500356A (zh) * 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032632A2 (en) * 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
US20070249631A1 (en) * 2004-04-28 2007-10-25 Gruenenthal Gmbh Substituted 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine-2-yl compounds and 5,6,7,8-tetrahydroquinazoline-2-yl compounds
WO2006119504A2 (en) * 2005-05-04 2006-11-09 Renovis, Inc. Fused heterocyclic compounds, and compositions and uses thereof
WO2012009258A2 (en) * 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators

Also Published As

Publication number Publication date
WO2014110000A1 (en) 2014-07-17
JP2016505010A (ja) 2016-02-18
MX2015008971A (es) 2015-09-28
EP2943494B1 (en) 2017-02-22
JP6285461B2 (ja) 2018-02-28
ES2636248T3 (es) 2017-10-05
EA201591098A1 (ru) 2015-11-30
US8969555B2 (en) 2015-03-03
TWI499591B (zh) 2015-09-11
BR112015015812A2 (pt) 2017-07-11
EA025106B1 (ru) 2016-11-30
KR20150092761A (ko) 2015-08-13
CN104903327A (zh) 2015-09-09
KR101757997B1 (ko) 2017-07-13
EP2943494A1 (en) 2015-11-18
CA2893253A1 (en) 2014-07-17
CA2893253C (en) 2017-11-28
US20140200231A1 (en) 2014-07-17
AU2014205642B2 (en) 2016-02-25
TW201437209A (zh) 2014-10-01
AU2014205642A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
CN104903327B (zh) 用于治疗疼痛的作为autotaxin抑制剂的吡啶并-或吡咯并-稠合嘧啶衍生物
CN101362765B (zh) 具有PDE-5抑制活性的5,7-二氨基吡唑并[4,3-d]嘧啶
EP3083618B1 (en) Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
EP1812439B2 (en) Kinase inhibitors
JP6133491B2 (ja) ジヒドロピリドピリミジン化合物
JP6163248B2 (ja) イミダゾピリジン化合物
JP6600365B2 (ja) Ｊａｋ阻害剤
JP2022512779A (ja) 二環式ペプチドリガンドおよびその使用
CA2908098A1 (en) Mk2 inhibitors and uses thereof
MXPA03004717A (es) Compuestos especificos para el receptor a1, a2 y a3 de adenosina y usos de los mismos.
JP2007502307A (ja) グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
CN109134463B (zh) β-咔啉类5型磷酸二酯酶抑制剂及其制备方法和用途
IL269214A (en) Imidazo [5,4-C] quinoline derivatives are new as LRRK2 inhibitors
BR112018015191B1 (pt) Compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida, seu uso e composição farmacêutica que os compreende
JP6900406B2 (ja) Ａｋｔ阻害剤としてのジヒドロピラゾロアゼピン系化合物
EP1191028B1 (en) Tricyclic compounds having spiro union
US20040063716A1 (en) Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds
CA3203922A1 (en) Enzyme inhibitors
CN104995183B (zh) 新的磷酸二酯酶10a型的抑制剂化合物
US20030045520A1 (en) Tricyclic compound having spiro union
JP7340542B2 (ja) １－イミダゾチアジアゾロ－２ｈ－ピロール－５－オン誘導体
EP4194450A1 (en) Cdk9 inhibitor and use thereof

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant